Abingworth has raised 11 funds dedicated to investing in life sciences and healthcare. Our most recent, Abingworth Clinical Co-Development Fund and Abingworth Bioventures VI, raised $108 million and £225 million ($375 million) respectively and are actively investing.
Our venture funds invest across our broad strategic areas of venture capital, pharmaceutical co-development, VIPEs and public markets. They focus primarily on private companies but are able to invest a percentage of their value in public companies.
Public Market Fund
Abingworth BioEquities (ABE) is dedicated solely to investing in public life science companies. Employing a long-only investment approach, our open-ended fund invests worldwide in public small-cap life sciences companies taking leadership positions in syndicated deals, participating in private placements as well as buying and selling shares in the open market.